{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:32:47Z","timestamp":1791988367377,"version":"4.4.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"46","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000403","name":"Meningitis Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000403","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.vaccine.2018.09.058","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T13:44:51Z","timestamp":1538660691000},"page":"7033-7042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Cost-effectiveness analysis of maternal immunisation against group B Streptococcus (GBS) disease: A modelling study"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5925-1846","authenticated-orcid":false,"given":"Kyriaki","family":"Giorgakoudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamez","family":"Ladhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Lamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hareth","family":"Al-Janabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4000-2708","authenticated-orcid":false,"given":"Caroline","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.09.058_b0005","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1093\/cid\/ciu514","article-title":"Incidence, etiology, and outcome of bacterial meningitis in infants aged <90 days in the United Kingdom and Republic of Ireland: prospective, enhanced, national population-based surveillance","volume":"59","author":"Okike","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.058_b0010","first-page":"A2","article-title":"P3 Group B Streptococcal (GBS) disease in UK and Irish infants younger than 90 days, 2014\u20132015","volume":"101","author":"O\u2019Sullivan","year":"2016","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2018.09.058_b0015","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(03)15389-5","article-title":"Group B streptococcal disease in UK and Irish infants younger than 90 days","volume":"363","author":"Heath","year":"2004","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2018.09.058_b0020","first-page":"2011","article-title":"Long-term outcomes of group B streptococcal meningitis","volume":"peds","author":"Libster","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.09.058_b0025","doi-asserted-by":"crossref","DOI":"10.1111\/1471-0528.13527","article-title":"Maternal group B Streptococcus-related stillbirth: a systematic review","author":"Nan","year":"2015","journal-title":"BJOG Int J Obstet Gynaecol"},{"key":"10.1016\/j.vaccine.2018.09.058_b0030","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1093\/cid\/cix653","article-title":"Group B Streptococcal disease worldwide for pregnant women, stillbirths, and children: why, what, and how to undertake estimates?","volume":"65","author":"Lawn","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.058_b0035","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/QCO.0b013e328360dc31","article-title":"Genitourinary pathogens and preterm birth","volume":"26","author":"Cunnington","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.058_b0040","doi-asserted-by":"crossref","first-page":"e012323","DOI":"10.1136\/bmjopen-2016-012323","article-title":"Maternal morbidity and mortality from severe sepsis: a national cohort study","volume":"6","author":"Acosta","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2018.09.058_b0045","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S1473-3099(16)30055-X","article-title":"Prevalence of maternal colonisation with group B streptococcus: a systematic review and meta-analysis","volume":"16","author":"Kwatra","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.058_b0050","doi-asserted-by":"crossref","first-page":"D7","DOI":"10.1016\/j.vaccine.2013.01.009","article-title":"An overview of global GBS epidemiology","volume":"31","author":"Le Doare","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.058_b0055","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/cid\/cit337","article-title":"Emerging trends in the epidemiology of invasive group B streptococcal disease in England and Wales, 1991\u20132010","volume":"57","author":"Lamagni","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.058_b0060","volume":"36","author":"Royal College of Obstetricians and Gynaecologists","year":"2012","journal-title":"Green-Top Guidel"},{"key":"10.1016\/j.vaccine.2018.09.058_b0065","unstructured":"The UK NSC recommendation on Group B Streptococcus screening in pregnancy; 2017. https:\/\/legacyscreening.phe.org.uk\/groupbstreptococcus [accessed 27 November 2017]."},{"key":"10.1016\/j.vaccine.2018.09.058_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2016.12.029","article-title":"WHO consultation on group B Streptococcus vaccine development: report from a meeting held on 27\u201328 April 2016","author":"Kobayashi","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.058_b0075","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/bmj.39325.681806.AD","article-title":"Preventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses","volume":"335","author":"Colbourn","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2018.09.058_b0080","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.vaccine.2014.01.062","article-title":"Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa","volume":"32","author":"Kim","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.058_b0085","doi-asserted-by":"crossref","first-page":"6905","DOI":"10.1016\/j.vaccine.2017.07.108","article-title":"Cost-effectiveness of maternal GBS immunization in low-income sub-Saharan Africa","volume":"35","author":"Russell","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.058_b0090","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1016\/j.vaccine.2014.06.003","article-title":"Prevention of group B streptococcal disease in the first 3 months of life: would routine maternal immunization during pregnancy be cost-effective?","volume":"32","author":"Oster","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.058_b0095","doi-asserted-by":"crossref","first-page":"6238","DOI":"10.1016\/j.vaccine.2017.08.085","article-title":"Cost-effectiveness of a potential group B streptococcal vaccine for pregnant women in the United States","volume":"35","author":"Kim","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.058_b0100","unstructured":"Office for National Statistics. Statistical bulletin: births in England and Wales, 2014; 2015."},{"key":"10.1016\/j.vaccine.2018.09.058_b0105","unstructured":"Northern Ireland Statistics & Research Agency. Vital statistics. Births. Table 3.10. Live births, stillbirths and maternities, by sex of child, marital status of parents and age of mother; 2012."},{"key":"#cr-split#-10.1016\/j.vaccine.2018.09.058_b0110.1","unstructured":"National Records of Scotland. Vital events reference tables 2014. Section 3: births. Table 3.14"},{"key":"#cr-split#-10.1016\/j.vaccine.2018.09.058_b0110.2","unstructured":"2014. http:\/\/www.nrscotland.gov.uk\/_les\/\/statistics\/vital-events-reftables\/2014\/section-3\/14-vital-events-ref-tab-3-14.pdf [accessed 27 May 2016]."},{"key":"10.1016\/j.vaccine.2018.09.058_b0115","unstructured":"Office for National Statistics. Statistical bulletin: national life tables, United Kingdom 2012\u20132014; 2015."},{"key":"10.1016\/j.vaccine.2018.09.058_b0120","unstructured":"Northern Ireland Statistics & Research Agency. Registrar general annual report 2014. Stillbirths and infant deaths; n.d. Available from\u202f: http:\/\/www.nisra.gov.uk\/demography\/default.asp99.htm [Accessed 27 May 2016]."},{"key":"10.1016\/j.vaccine.2018.09.058_b0125","unstructured":"General Register Office for Scotland. Vital events reference tables 2012. Section 4: stillbirths and infant deaths. Table 4.1; 2013. Available from: http:\/\/www.gro-scotland.gov.uk\/files2\/stats\/ve-ref-tables-2012\/ve12-t4-1.pdf [accessed 30 June 2014]."},{"key":"10.1016\/j.vaccine.2018.09.058_b0130","unstructured":"Royal College of Obstetricians and Gynaecologists, Royal College of Obstetricians and Gynaecologists. Group B streptococcal disease, early-onset; 2017."},{"key":"10.1016\/j.vaccine.2018.09.058_b0135","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID). A phase II randomized, double-blinded, comparative clinical trial for a group B Streptococcus serotype III-tetanus toxoid (GBS III-TT) vaccine to prevent vaginal acquisition of GBS type III; 2009. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00128219?term=GBS+studies&sect=X470156 [accessed 7 August 2016]."},{"key":"10.1016\/j.vaccine.2018.09.058_b0140","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1473-3099(16)00152-3","article-title":"Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b\/2 trial","volume":"16","author":"Madhi","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.058_b0145","unstructured":"JCVI. Code of practice; June 2013. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/224864\/JCVI_Code_of_Practice_revision_2013_-_final.pdf [accessed 27 November 2014]."},{"key":"10.1016\/j.vaccine.2018.09.058_b0160","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3233\/NRE-2003-18310","article-title":"Life expectancy for children with cerebral palsy and mental retardation: implications for life care planning","volume":"18","author":"Katz","year":"2003","journal-title":"NeuroRehabilitation"},{"key":"10.1016\/j.vaccine.2018.09.058_b0165","unstructured":"Lamagni T, Guy R, Wloch C, Shetty N, Chalker V, Johnson A. Estimating the burden of group B streptococcal (GBS) maternal sepsis in England. Federation of Infection Societies (FIS) Annual Conference and the 10th Healthcare Infection Society (HIS) International Conference 2016, 6 November 2016, Edinburgh; n.d."},{"key":"10.1016\/j.vaccine.2018.09.058_b0170","unstructured":"Public Health England. Vaccine update. Issue 217; 2014."},{"key":"10.1016\/j.vaccine.2018.09.058_b0175","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S0140-6736(14)60686-3","article-title":"Effectiveness of maternal pertussis vaccination in England: an observational study","volume":"384","author":"Amirthalingam","year":"2014","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2018.09.058_b0180","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1016\/j.vaccine.2008.05.073","article-title":"Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae","volume":"26","author":"Trotter","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.058_b0185","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1001\/jama.1993.03510120064032","article-title":"Comparison of prevention strategies for neonatal group b streptococcal infection: a population-based economic analysis","volume":"270","author":"Mohle-Boetani","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2018.09.058_b0190","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10198-008-0131-4","article-title":"The economic costs of Group B Streptococcus (GBS) disease: prospective cohort study of infants with GBS disease in England","volume":"10","author":"Schroeder","year":"2009","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.vaccine.2018.09.058_b0195","unstructured":"Curtis L. Unit costs of health and social care 2014; n.d."},{"key":"10.1016\/j.vaccine.2018.09.058_b0200","unstructured":"Department of Health. NHS reference costs 2013\u20132014; n.d. https:\/\/www.gov.uk\/government\/publications\/nhs-reference-costs-2013-to-2014 [accessed 27 April 2016]."},{"key":"10.1016\/j.vaccine.2018.09.058_b0205","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40272-012-0006-0","article-title":"Counting the cost of meningococcal disease. Scenarios of severe meningitis and septicemia","volume":"15","author":"Wright","year":"2013","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.vaccine.2018.09.058_b0210","doi-asserted-by":"crossref","first-page":"g5725","DOI":"10.1136\/bmj.g5725","article-title":"Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study","volume":"349","author":"Christensen","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2018.09.058_b0215","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2214.2012.01368.x","article-title":"The association between neurodevelopmental disability and economic outcomes during mid-childhood","volume":"39","author":"Petrou","year":"2013","journal-title":"Child Care Health Dev"},{"key":"#cr-split#-10.1016\/j.vaccine.2018.09.058_b0220.1","unstructured":"NHS Employers. Vaccination and immunisation programmes 2016\/17. Guidance and audit requirements, May 2016"},{"key":"#cr-split#-10.1016\/j.vaccine.2018.09.058_b0220.2","unstructured":"n.d. http:\/\/www.nhsemployers.org\/\/media\/Employers\/Documents\/Primary [accessed 1 June 2016]."},{"key":"10.1016\/j.vaccine.2018.09.058_b0225","unstructured":"NHS Litigation Authority. Freedom of information request F\/2649; n.d."},{"key":"10.1016\/j.vaccine.2018.09.058_b0230","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/adc.2011.212555","article-title":"An analysis of successful litigation claims in children in England","volume":"96","author":"Raine","year":"2011","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2018.09.058_b0235","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s00431-012-1793-6","article-title":"An analysis of successful litigation claims in childhood fatalities in England","volume":"171","author":"Sen","year":"2012","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.vaccine.2018.09.058_b0240","unstructured":"Meningitis Research Foundation. Response to the JCVI interim position statement on the use of Bexsero meningococcal B vaccine in the UK; n.d."},{"key":"10.1016\/j.vaccine.2018.09.058_b0245","doi-asserted-by":"crossref","first-page":"F85","DOI":"10.1136\/fn.84.2.F85","article-title":"Neonatal meningitis in England and Wales: 10 years on","volume":"84","author":"Holt","year":"2001","journal-title":"Arch Dis Child-Fetal Neonatal Ed"},{"key":"10.1016\/j.vaccine.2018.09.058_b0250","first-page":"11","article-title":"Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses","author":"Colbourn","year":"2007","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.vaccine.2018.09.058_b0255","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199008303230906","article-title":"The life expectancy of profoundly handicapped people with mental retardation","volume":"323","author":"Eyman","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.09.058_b0260","unstructured":"Office for National Statistics. National life tables: United Kingdom; 2015."},{"key":"10.1016\/j.vaccine.2018.09.058_b0265","series-title":"Unit costs of health and social care","author":"Curtis","year":"2015"},{"key":"10.1016\/j.vaccine.2018.09.058_b0270","doi-asserted-by":"crossref","first-page":"e007976","DOI":"10.1136\/bmjopen-2015-007976","article-title":"Severe sepsis in women with group B Streptococcus in pregnancy: an exploratory UK national case-control study","volume":"5","author":"Kalin","year":"2015","journal-title":"BMJ Open."},{"key":"10.1016\/j.vaccine.2018.09.058_b0275","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1093\/cid\/cix660","article-title":"Maternal disease with group B Streptococcus and serotype distribution worldwide: systematic review and meta-analyses","volume":"65","author":"Hall","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.058_b0280","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/0272989X15605094","article-title":"A framework for including family health spillovers in economic evaluation","volume":"36","author":"Al-Janabi","year":"2016","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.vaccine.2018.09.058_b0285","unstructured":"The Department of Health Guidance Manual to Impact Assessments; 2015."},{"key":"10.1016\/j.vaccine.2018.09.058_b0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19140","article-title":"Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold","volume":"19","author":"Claxton","year":"2015","journal-title":"Health Technol Assess Winch Engl"},{"key":"10.1016\/j.vaccine.2018.09.058_b0295","unstructured":"Public Health England. Pertussis vaccination programme for pregnant women: vaccine coverage estimates in England, April to August 2014; n.d. https:\/\/www.gov.uk\/government\/publications\/pertussis-immunisation-in-pregnancy-vaccine-coverage-estimates-in-england-october-2013-to-march-2014\/pertussis-vaccination-programme-for-pregnant-women-vaccine-coverage-estimates-in-england-april-to-august-2014#results [accessed 29 September 2017]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18313276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18313276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T01:29:03Z","timestamp":1605144543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18313276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":59,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0264410X18313276"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.09.058","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of maternal immunisation against group B Streptococcus (GBS) disease: A modelling study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.09.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2018 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}